IXICO, the digital technologies company serving neuroscience, has announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD). Sponsored by specialist Spanish biotech company Araclon Biotech, a Grifols company, this phase II of the study is designed to establish the dosage regimen for the therapy, as well as confirm the treatment safety and tolerability data obtained in phase I.
Using our TrialTracker digital platform, IXICO will collate both PET and MRI scans acquired at specialist imaging centres across Europe. This data will be then analysed using IXICO’s patent protected image analysis technology, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in AD patients.
Giulio Cerroni, chief executive of IXICO, commented: “We are delighted to be working with Araclon Biotech which continues our success in providing our customers with a solution that spans both PET and MR imaging services. It is a great example of IXICO’s growing value to the biopharmaceutical industry and reinforces our confidence in revenue growth this financial year.”
Manuel Sarasa, chief scientific officer of Araclon, commented: “It is an important milestone for us to initiate phase II of clinical trials for our Azheimer´s vaccine -ABvac40- after receiving approval from the Spanish Agency of Medicinal Products and Medical Service. We are a little closer to achieving our goal, so it is fundamental for us to incorporate the best-in-class suppliers, such as IXICO, to work together in this amazing project that is also supported by some Spanish institutions such as the Zaragoza University.”
Ixico signs new contract for specialist imaging clinical trial services
3.jpg)
